ArticleEuropean urology open science2026
Trends and Patterns in Prostate Cancer Diagnostics During the Era of MRI Implementation - Real-world Evidence From a Population-based Study in the Stockholm Region, Sweden 2010-2023.
Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Pre-biopsy magnetic resonance imaging (MRI) is recommended in prostate cancer diagnostics, but its impact on testing patterns and diagnostic outcomes on a population-level remains unclear. Methods: Using the Stockholm Prostate Cancer Diagnostics Register, we conducted a population-based study of men aged ≥40 yr without prior prostate cancer during 2010-2023. We described the trends in prostate-specific antigen (PSA) testing, the proportion of men with PSA ≥3 ng/ml undergoing further testing (MRI and/or biopsy), and the distribution of biopsy outcomes. Key findings and limitations: PSA testing was stable over time, with greater uptake observed in older men: in 2023, 14-yr prevalence was 76% in men aged 60-69 yr, and 84% in both those aged 70-79 and ≥80 yr. Among men with PSA ≥3 ng/ml, MRI within 1 yr increased from 3% in 2010 to 30% in 2023, while the proportion undergoing prostate biopsy declined from 23% to 16% (relative risk [RR]: 0.71; 95% confidence interval [CI]: 0.69-0.73). By 2023, 83% of biopsied men had a pre-biopsy MRI. Over the study period, biopsy outcomes improved: detection of International Society of Urological Pathology [ISUP] grade group [GG] ≥2 cancers more than doubled (RR: 2.12; 95% CI: 1.99-2.27), whereas both benign biopsies (RR: 0.66; 95% CI: 0.62-0.69) and ISUP GG 1 (RR: 0.61; 95% CI: 0.54-0.69) declined markedly. Conclusions and clinical implications: PSA testing remained prevalent, and pre-biopsy MRI use increased substantially. During this period, detection of significant cancer among biopsied men increased markedly while unnecessary biopsies and low-grade cancer findings decreased. This study provides real-world population-based data that are consistent with a trend toward increased precision in prostate cancer diagnostics in the era of MRI implementation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.